Novartis: bio-similar Zessly approved in Europe
(CercleFinance.com) - Novartis today announces that Sandoz, its biosimilar division, has received approval from the European Commission for the use of Zessly (infliximab) in Europe, an approval that covers all indications for the reference medicinal product.
It can be used in the treatment of diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
"Zessly is the sixth approved biosimilar medicine for Sandoz, with several more major oncology and immunology launches expected globally by 2020," said the Swiss pharmaceuticals group.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
It can be used in the treatment of diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
"Zessly is the sixth approved biosimilar medicine for Sandoz, with several more major oncology and immunology launches expected globally by 2020," said the Swiss pharmaceuticals group.
Copyright (c) 2018 CercleFinance.com. All rights reserved.